November 8, 2015 | Israeli bio-med company Vascular Biogenics raised $15 million following the closure of its stock offering of 2,500,000 ordinary shares at $6.00 per share. The company intends to use the net proceeds from the offering for the advancement of clinical programs, and for working capital. Founded in 2000 by CEO Prof. Dror Harats, Vascular Biogenics is a late-stage clinical bio-pharmaceutical company focused on the discovery, development and commercialization of gene-based treatments for cancer, including their lead drug, VB-111 that is being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

US Soldiers, Vets To Get Israeli-Made Helmets To Treat Depression
September 27, 2023

Israeli Startups Raise $1.6B in Q3, Indicating Stabilization - Report
September 27, 2023

Global Chip Maker Buying Renewable Energy From Israeli Firm
September 27, 2023

VC Fund Raises $480M For Cybersecurity Investment
September 26, 2023
Facebook comments